Blueprint guts lung cancer portfolio, pulling Gavreto in certain markets
2024-01-09
并购加速审批上市批准引进/卖出
Blueprint Medicines is deprioritising some lung cancer programmes, citing an "evolving external landscape, emerging clinical data and partnering considerations." In an update at the ongoing JP Morgan healthcare conference, Blueprint said it would be scaling back Gavreto (pralsetinib) in certain markets, and culling a pair of early-stage assets.
Last year, Roche terminated a collaboration between the companies due to strategic considerations and handed back global commercialisation and development rights for Gavreto, which is approved in the US to treat RET fusion-positive populations of non-small-cell lung cancer (NSCLC) and thyroid cancer. Gavreto had also received FDA accelerated approval for RET-mutant medullary thyroid cancer, but the partners withdrew the oral RET inhibitorRET inhibitor for the indication last summer.
Another partner to the rescue?
Citing a lack of global infrastructure in lung and thyroid cancer, Blueprint now says it has decided to discontinue global development and marketing of Gavreto in territories excluding the US and China. It expects to begin winding down activities in the first quarter of 2024. An alternate partner for Gavreto in the US may be waiting in the wings, however; Blueprint said it is working with the parties involved to define a scenario that would allow the drug to continue to be available in the country.
The move won't affect the $175-million upfront payment Blueprint received under a 2022 financing agreement with Royalty Pharma.
Meanwhile, Blueprint also hinted that "emerging clinical data" spurred a decision to discontinue investing in the early-stage therapies BLU-945 and BLU-451 for EGFR-mutant NSCLC. The company got hold of BLU-451 via its purchase of Lengo Therapeutics in 2021 for up to $465 million, elbowing its way into an increasingly crowded niche within lung cancer.
It is now considering different options for the assets, including potential out-licensing. That leaves BLU-525, another EGFR inhibitorEGFR inhibitor, as Blueprint's sole pipeline candidate for lung cancer, according to its website.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。